• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Germany Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Germany Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373231
  • January 2013
  • Region: Germany
  • 112 pages
  • Business Monitor International

FEATURED COMPANIES

  • Bayer HealthCare
  • Company Profiles
  • Grünenthal
  • Merck & Co
  • Multinational Companies
  • Pfizer
  • MORE

BMI View:

While the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) legislation will compress drug companies' revenue-earning opportunities in Germany, we believe the government's decision to make the final reimbursement prices of medicines sold in the country publicly available, and the use of reference pricing across the region, will also lead to price reductions in other countries, providing an aggregation of pricing pressures on companies operating throughout Europe. For its part, the German pharmaceutical market is expected to decline in value by a compound annual growth rate (CAGR) of 0.5% through to 2016, as expressed in local currency terms, or by 3.4% in US dollars.

Headline Expenditure Projections

- Pharmaceuticals: EUR39.67bn (US$55.15bn) in 2011 to EUR38.65bn (US$49.08bn) in 2012;
-2.6% in local currency terms and -11.0% in US dollar terms. Forecast unchanged from Q412.

- Healthcare: EUR272.67bn (US$379.01bn) in 2011 to EUR279.09bn (US$354.44bn) in 2012;
+2.4% in local currency terms and -6.5% in US dollar terms. Forecast unchanged from Q412.

- Medical devices: EUR14.97bn (US$20.81bn) in 2011 to EUR15.62bn (US$19.83bn) in 2012;
+4.3% READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer HealthCare
  • Company Profiles
  • Grünenthal
  • Merck & Co
  • Multinational Companies
  • Pfizer
  • MORE

Executive Summary 7

SWOT Analysis 9

Germany Pharmaceuticals And Healthcare Industry SWOT 9

Germany Political SWOT 10

Germany Economic SWOT 10

Germany Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12
Table: Western Europe Pharmaceutical Risk/Reward Ratings, Q113 12

Rewards 13

Risks 14

Germany - Market Summary 15

Regulatory Regime 16
Table: BfArM Drug Registration Activity, 2006-10 16

Intellectual Property Regime 18

Pricing Regime 19
Table: Price Build-Up In The German Pharmaceutical Market 19

Pricing Developments 20
Table: AMNOG Drug Assessments 21

Reimbursement Regime 24
Table: Top 10 GKV Selling Drug Brands, 2009-2010 (EURmn) 25

Reimbursement Developments 27

Parallel Imports 28

Industry Developments 29

Epidemiology 29

Healthcare Sector 30

Health Insurance 30

Healthcare Sector Reforms 30

Research & Development 32

Biotechnology Sector 36
Table: Biotechnology Sector, 2008-09 36

Clinical Trials 38

Medical Devices Industry 38

Developments In The Medical Devices Industry 39

Industry Forecast Scenario 41

Overall Market Forecast 41
Table: Pharmaceutical Sales Indicators 2008-2016 42

Healthcare Market Forecast 43
Table: Healthcare Expenditure Indicators 2008-2016 44
Table: Healthcare Governmental Indicators 2008-2016 44
Table: Healthcare Private Indicators 2008-2016 45

Key Growth Factors - Macroeconomic 46
Table: Germany -GDP By ]Expenditure, Real Growth % 51

Prescription Drug Market Forecast 52
Table: Retail Pharmaceutical Expenditure, 2003-10 (Euro Billions) 52
Table: Retail Pharmaceutical Expenditure, 2003-10 (Packages, Millions) 53
Table: Retail Pharmaceutical Expenditure, 2003-10 (Average Price per Pack, Euros) 53
Table: Prescription Drug Sales Indicators 2008-2016 54

Patented Drug Market Forecast 55
Table: Patented Drug Market Indicators 2008-2016 56

Generic Drug Market Forecast 57
Table: Generic Drug Sales Indicators 2008-2016 59

OTC Medicine Market Forecast 60
Table: OTC Medicine Sales Indicators 2008-2016 60
Table: OTC Market by Leading Categories, 2004-2010 (EURmn) 61

Pharmaceutical Trade Forecast 62
Table: Exports and Imports Indicators 2009-2016 63

Medical Device Market Forecast 64
Table: Medical Devices Sales Indicators 2009-2016 65

Other Healthcare Data 66

Key Risks To BMI's Forecast Scenario 67

Competitive Landscape 68

Pharmaceutical Industry 68
Table: Pharmaceutical Production, 1990-10 68
Table: Leading German Pharmaceutical Companies 69

Company Developments 70

Wholesale Sector 70
Table: Members of the Association of Pharmaceutical Wholesalers (PHAGRO), 2012 71

Wholesale Sector Developments 73

Retail Sector 74

Retail Sector Developments 76

Company Profiles 78

Local Companies 78

Bayer HealthCare 78

Boehringer Ingelheim 82

Stada Arzneimittel 86

Grünenthal 90

Merck KGaA 91

Multinational Companies 95

GlaxoSmithKline (GSK) 95

Pfizer 97

Novartis 99

Sanofi 00

Merck & Co 02
Table: Population By Age Group, 1990-2020 ('000) 03
Table: Population By Age Group, 1990-2020 (% of total) 04
Table: Key Population Ratios, 1990-2020 05
Table: Rural And Urban Population, 1990-2020 05

Glossary 106

BMI Methodology 108

How We Generate Our Pharmaceutical Industry Forecasts 08

Risk/Reward Ratings Methodology 09

Ratings Overview 09
Table: Pharmaceutical Business Environment Indicators 10

Weighting 11
Table: Weighting Of Components 11

Sources 11

Note: Product cover images may vary from those shown

Company Profiles
Local Companies
Bayer HealthCare
Boehringer Ingelheim
Stada Arzneimittel
Grünenthal
Merck KGaA
Multinational Companies
GlaxoSmithKline (GSK)
Pfizer
Novartis
Sanofi
Merck & Co

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos